The effect of Liraglutide treatment on postprandial chylomicron and VLDL kinetics, liver fat and de novo lipogenesis. A single-center randomized controlled study.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms LIRA
- 31 Aug 2018 Biomarkers information updated
- 24 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 24 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2022.